# EV-309 (NCT07566156)

> Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07566156
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Urothelial Cancer; Urinary Bladder Neoplasms
- Interventions: Enfortumab vedotin; Conventional Radiotherapy; Hypofractionated Radiotherapy; Cisplatin; Fluorouracil; Mitomycin C; Gemcitabine; Pembrolizumab
- Enrollment: 390
- Primary outcome: Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on EV-309 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 14
- YouTube: 5
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ev-309-nct07566156

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07566156", "email": "<work email>"}; the inbox owner confirms by the emailed link.